151 related articles for article (PubMed ID: 10184933)
1. Primary prevention.
Am J Manag Care; 1998 Apr; 4(4 Suppl):S185-90. PubMed ID: 10184933
[No Abstract] [Full Text] [Related]
2. Secondary prevention.
Am J Manag Care; 1998 Apr; 4(4 Suppl):S201-8. PubMed ID: 10184934
[No Abstract] [Full Text] [Related]
3. Pharmacoeconomics perspectives: payers, providers, and patients.
Am J Manag Care; 1998 Apr; 4(4 Suppl):S221-4. PubMed ID: 10184937
[No Abstract] [Full Text] [Related]
4. Preventing coronary artery disease in the West of Scotland: implications for primary prevention.
Shepherd J
Am J Cardiol; 1998 Nov; 82(10B):57T-59T. PubMed ID: 9860377
[TBL] [Abstract][Full Text] [Related]
5. [Victory in primary prevention--or? Can we afford to translate results from the West-of-Scotland Study into general practice?].
Klose G
Fortschr Med; 1996 Jun; 114(17):231-2. PubMed ID: 8767302
[No Abstract] [Full Text] [Related]
6. Forecasting cholesterol management--end of the statin gold rush?
Crownover BK; Curtiss FR
J Manag Care Pharm; 2006; 12(6):479-85. PubMed ID: 16925456
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of coronary prevention.
Szucs TD; März W
Eur Heart J; 1999 Feb; 20(4):317-8. PubMed ID: 10099929
[No Abstract] [Full Text] [Related]
8. Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study.
Caro JJ; Huybrechts KF; De Backer G; De Bacquer D; Closon MC
Acta Cardiol; 2000 Aug; 55(4):239-46. PubMed ID: 11041122
[TBL] [Abstract][Full Text] [Related]
9. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.
Caro J; Klittich W; McGuire A; Ford I; Norrie J; Pettitt D; McMurray J; Shepherd J
BMJ; 1997 Dec; 315(7122):1577-82. PubMed ID: 9437275
[TBL] [Abstract][Full Text] [Related]
10. Clinical and economic considerations of coronary heart disease: a managed care approach. Proceedings based on presentations from two conferences, Cardiovascular Event Reduction: Defining the Role of HMG Therapy in Managed Care, held November 14-16, 1997 in Philadelphia, and Pharmacoeconomics & Outcomes Issues of Lipid Therapy, held November 5-7, 1997 in Orlando.
Am J Manag Care; 1998 Apr; 4(4 Suppl):S168-233. PubMed ID: 10180343
[No Abstract] [Full Text] [Related]
11. Prevention of coronary heart disease with pravastatin.
Rogers S
N Engl J Med; 1996 May; 334(20):1333; author reply 1334-5. PubMed ID: 8609956
[No Abstract] [Full Text] [Related]
12. Primary prevention of coronary artery disease.
Domanski MJ
N Engl J Med; 2007 Oct; 357(15):1543-5. PubMed ID: 17928603
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model.
Muls E; Van Ganse E; Closon MC
Atherosclerosis; 1998 Apr; 137 Suppl():S111-6. PubMed ID: 9694550
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease.
Ashraf T; Hay JW; Pitt B; Wittels E; Crouse J; Davidson M; Furberg CD; Radican L
Am J Cardiol; 1996 Aug; 78(4):409-14. PubMed ID: 8752184
[TBL] [Abstract][Full Text] [Related]
16. [Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial].
Szucs TD; Berger K; März W; Schäfer JR
Herz; 2000 Aug; 25(5):487-94. PubMed ID: 10992997
[TBL] [Abstract][Full Text] [Related]
17. Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS).
Lim PO; Yee KM
Circulation; 1999 Aug; 100(6):686. PubMed ID: 10441109
[No Abstract] [Full Text] [Related]
18. Therapy and clinical trials.
Bhatnagar D
Curr Opin Lipidol; 1997 Jun; 8(3):U44-6. PubMed ID: 9211075
[No Abstract] [Full Text] [Related]
19. Recent developments in coronary heart disease prevention: the Scandinavian and west of Scotland studies.
Elam MB; Cushman W; Applegate WB; Heimberg M
Tenn Med; 1997 May; 90(5):189-92. PubMed ID: 9130876
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels.
Tsevat J; Kuntz KM; Orav EJ; Weinstein MC; Sacks FM; Goldman L
Am Heart J; 2001 May; 141(5):727-34. PubMed ID: 11320359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
